Advertisement

The association of PRECISE-DAPT score with development of contrast-induced nephropathy in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

  • Tufan ÇınarEmail author
  • Veysel Ozan Tanık
  • Emre Aruğaslan
  • Yavuz Karabağ
  • Metin Çağdaş
  • İbrahim Rencüzoğulları
  • Muhammed Keskin
Original Article
  • 82 Downloads

Abstract

Given that parameters used in the calculation of the PRECISE-DAPT risk score are important contributors to contrast-induced nephropathy (CIN) development, we hypothesized that the PRECISE-DAPT risk score would show good accuracy for predicting CIN in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Therefore, in this study, we aimed to determine the predictive value of the admission PRECISE-DAPT score for the occurrence of CIN in patients with STEMI treated with primary PCI. After evaluation regarding with exclusion criteria, 1280 patients were, respectively, enrolled in the study. The primary end-point was the incidence of CIN. The PRECISE-DAPT score of CIN group was higher than the non-CIN group [31 (24–41) vs. 14 (9–23), p < 0.001, respectively]. In multivariate logistic regression analysis, PRECISE-DAPT score was independently associated with the development of CIN [odds ratio (OR) 1.090, 95% confidence interval (CI) 1.066–1.114, p < 0.001]. A receiver-operating characteristic (ROC) analysis was drawn to show the best cut-off value of the PRECISE-DAPT score to predict CIN was ≥ 21 with 81.3% sensitivity and 72.7% specificity [area under curve (AUC): 0.834; 95% CI 0.812–0.854; p = 0.017]. The PRECISE-DAPT score may be a significant independent predictor of CIN in patients with STEMI treated with primary PCI. Therefore, follow-up of patients with higher PRECISE-DAPT score should be performed more cautiously, and it should be noted that the development of CIN risk of these patients group is high.

Keywords

PRECISE-DAPT score ST-elevation myocardial infarction Contrast-induced nephropathy Primary percutaneous coronary intervention 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare that they do not have any conflict of interest.

Ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

The need for written informed consent was waived due to retrospective study design.

References

  1. 1.
    Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2569–619.CrossRefGoogle Scholar
  2. 2.
    Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1780–5.CrossRefGoogle Scholar
  3. 3.
    Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;100:11–5.CrossRefGoogle Scholar
  4. 4.
    Pucelikova T, Dangas G, Mehran R. Contrast-induced nephropathy. Catheter Cardiovasc Interv. 2008;71:62–72.CrossRefGoogle Scholar
  5. 5.
    Yuan Y, Qiu H, Hu X, Luo T, Gao X, Zhao X, et al. Predictive value of inflammatory factors on contrast-induced acute kidney injury in patients who underwent an emergency percutaneous coronary intervention. Clin Cardiol. 2017;40:719–25.CrossRefGoogle Scholar
  6. 6.
    Shacham Y, Gal-Oz A, Leshem-Rubinow E, Arbel Y, Flint N, Keren G, et al. Association of admission hemoglobin levels and acute kidney injury among myocardial infarction patients treated with primary percutaneous intervention. Can J Cardiol. 2015;31:50–5.CrossRefGoogle Scholar
  7. 7.
    Kwasa EA, Vinayak S, Armstrong R. The role of inflammation in contrast-induced nephropathy. Br J Radiol. 2014;87:20130738.CrossRefGoogle Scholar
  8. 8.
    Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual patient data sets from clinical trials. Lancet. 2017;389:1025–34.CrossRefGoogle Scholar
  9. 9.
    Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Chronic kidney disease epidemiology collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.CrossRefGoogle Scholar
  10. 10.
    Thygesen K, Alpert JS, White HD. ESC, Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551–67.CrossRefGoogle Scholar
  11. 11.
    Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of Arterial hypertension of the European society of hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.CrossRefGoogle Scholar
  12. 12.
    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87.CrossRefGoogle Scholar
  13. 13.
    Koskinas KC. Effect of Statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39:1172–80.CrossRefGoogle Scholar
  14. 14.
    Nutritional anemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;405:5–37.Google Scholar
  15. 15.
    Andrassy KM. Comments on KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;84:622–3.CrossRefGoogle Scholar
  16. 16.
    McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51:1419–28.CrossRefGoogle Scholar
  17. 17.
    Raposeiras-Roubín S, Aguiar-Souto P, Barreiro-Pardal C, López Otero D, Elices Teja J, OcaranzaSanchez R, et al. GRACE risk score predicts contrast-induced nephropathy in patients with acute coronary syndrome and normal renal function. Angiology. 2013;64:31–9.CrossRefGoogle Scholar
  18. 18.
    Bouzas-Mosquera A, Vázquez-Rodríguez JM, Calvino-Santos R, Peteiro-Vázquez J, Flores-Ríos X, Marzoa-Rivas R, et al. Contrast-induced nephropathy and acute renal failure following urgent cardiac catheterization: incidence, risk factors, and prognosis. Rev Esp Cardiol. 2007;60:1026–34.CrossRefGoogle Scholar
  19. 19.
    Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393–9.Google Scholar
  20. 20.
    Narula A, Mehran R, Weisz G, Dangas GD, Yu J, Généreux P, et al. Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. Eur Heart J. 2014;35:1533–40.CrossRefGoogle Scholar
  21. 21.
    Nozue T, Michishita I, Iwaki T, Mizuguchi I, Miura M. Contrast medium volume to estimated glomerular filtration rate ratio as a predictor of contrast-induced nephropathy developing after elective percutaneous coronary intervention. J Cardiol. 2009;54:214–20.CrossRefGoogle Scholar
  22. 22.
    Anzai A, Anzai T, Naito K, Kaneko H, Mano Y, Jo Y, et al. Prognostic significance of acute kidney injury after reperfused ST-elevation myocardial infarction: synergistic acceleration of renal dysfunction and left ventricular remodelling. J Card Fail. 2010;16:381–99.CrossRefGoogle Scholar
  23. 23.
    Stolker JM, McCullough PA, Rao S, Inzucchi SE, Spertus JA, Maddox TM, et al. Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography. J Am Coll Cardiol. 2010;55:1433–40.CrossRefGoogle Scholar
  24. 24.
    Cicek G, Yıldırım E. CHA2DS2-VASc score predicts contrast induced nephropathy in patients with ST-segment elevation myocardial infarction who were undergoing primary percutaneous coronary intervention. Kardiol Pol. 2018;76:91–8.CrossRefGoogle Scholar
  25. 25.
    Valgimigli M, BuenoH Byrne RA, Collet JP, Collet JP, Costa F, Jeppsson A, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2017;2018(39):213–60.Google Scholar
  26. 26.
    Chong E, Poh KK, Lu Q, Zhang JJ, Tan N, Hou XM, Ong HY, Azan A, Chen SL, Chen JY, Ali RM, Fang WY, Lau TW, Tan HC. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterization and Percutaneous Coronary Intervention (CONTRAST): a multi-center, randomized, controlled trial. Int J Cardiol. 2015;201:237–42.CrossRefGoogle Scholar

Copyright information

© Japanese Association of Cardiovascular Intervention and Therapeutics 2018

Authors and Affiliations

  1. 1.Sultan Abdülhamid Han Training and Research Hospital, Health Sciences UniversityIstanbulTurkey
  2. 2.Ankara Dışkapı Yıldırım Beyazıt Training and Research HospitalAnkaraTurkey
  3. 3.Sivas Numune HospitalSivasTurkey
  4. 4.Department of CardiologyKafkas UniversityKafkasTurkey

Personalised recommendations